CAS 85979-33-5

N-[(1,1-dimethylethoxy)carbonyl]-D-Allothreonine

CAS : 85979-33-5

Formule : C₉H₁₇NO₅

Degré de pureté : 97%

Couleur et forme : Solid

Masse moléculaire : 219.2350

Ref: IN-DA008FWC

(2R,3R)-2-((tert-Butoxycarbonyl)amino)-3-hydroxybutanoic acid

CAS : 85979-33-5

(2R,3R)-2-((tert-Butoxycarbonyl)amino)-3-hydroxybutanoic acid

Degré de pureté : 97%

Ref: 54-OR1037978

(2R,3R)-2-((tert-Butoxycarbonyl)amino)-3-hydroxybutanoic acid

CAS : 85979-33-5

Degré de pureté : 97%

Masse moléculaire : 219.2369995

Ref: 10-F738136

(2R,3R)-2-{[(tert-Butoxy)carbonyl]amino}-3-hydroxybutanoic acid

CAS : 85979-33-5

Pf-06305591 is a benzimidazole blocker that is being developed for the treatment of epilepsy. Pf-06305591 blocks sodium channels in the central nervous system, which are involved in neuronal excitability and seizure generation. This drug has been shown to be safe and well tolerated in preclinical studies. Pf-06305591 was discovered by optimizing chemical structures of phenylimidazole blockers, which have been shown to have efficacy against seizures but with a high incidence of adverse effects. Pf-06305591 has been shown to be effective at a dose that is well tolerated, with an optimized safety profile that can be individualized according to the patient's needs.

Formule : C₉H₁₇NO₅

Degré de pureté : Min. 95%

Masse moléculaire : 219.23 g/mol

Ref: 3D-KDA97933